Company news

Genomtec SA news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

GMT: Net loss narrowed and revenue rose, but continued funding and market risks persist

June 1, 2026

GMT: Patent expansion, cost cuts, and narrowed loss set the stage for commercialization in 2026

April 30, 2026

GMT: Net loss persists as R&D spending rises; commercialization and funding remain critical

November 28, 2025

GMT: Net loss deepened to PLN 6.6M as R&D spending rose; commercialization still ahead

September 29, 2025

GMT: Genomtec's Q1 2025 loss widened as R&D ramped up, with commercialization still pending

May 29, 2025

GMT: Rapid genetic diagnostics, strong IP, and robust funding drive growth and M&A momentum

May 14, 2025

GMT: Net loss widened to PLN -11.2m as R&D continued, with equity raises ensuring 12+ months liquidity

April 29, 2025

GMT: Genomtec accelerates M&A, slashes production costs, and strengthens its position in diagnostics

December 11, 2024

GMT: Losses persist as Genomtec advances R&D, secures funding, and pursues M&A for commercialisation

November 29, 2024

GMT: Net loss widened to PLN 6.0 million in H1 2024 as Genomtec advanced R&D and raised new capital

September 26, 2024

Decks